Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Oral selective estrogen receptor degraders and estrogen receptor degraders
22 evidence topics · 23 sources
Guideline recommendation: NCCN, elacestrant and imlunestrant for ESR1-mutated disease
Guideline recommendation: NCCN, imlunestrant plus abemaciclib and vepdegestrant
Guideline recommendation: ABC8, oral SERD class
“Since the approval of elacestrant based on the EMERALD trial [ 33 ], the class of oral SERDs has expanded with new agents now supported by phase 3 evidence. Across this body of evidence, a consistent pattern emerges of modest absolute clinical benefit in ESR1-mutated tumors, with hazard ratios generally in the 0.55–0.62 range.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Camizestrant showed encouraging results in the SERENA-6 trial using a ctDNA-guided switch strategy upon emergence of ESR1 mutations , though the clinical utility of treatment modification without radiological progression remains to be established [ 35 ].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The oral route of administration and generally favorable tolerability of these agents represent meaningful advantages for patients, particularly compared to intramuscular fulvestrant. Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline background: ASCO 2021, ESR1 testing before oral SERD approvals
“There are insufficient data at present to recommend routine testing for ESR1 mutations to guide therapy for HR-positive, HER2-negative MBC. Existing data suggest reduced efficacy of AIs compared with the selective estrogen receptor degrader fulvestrant in patients who have tumor or circulating tumor DNA (ctDNA) with ESR1 mutations (type: informal consensus; evidence quality: insufficient; strength of recommendation: moderate).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: elacestrant
Elacestrant, EMERALD: trial population and comparator
Elacestrant, EMERALD: progression-free survival
“PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P = .002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P = .0005).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, 12-month PFS rates were 22.3% (95% CI, 15.2 to 29.4) versus 9.4% (95% CI, 4.0 to 14.8), respectively, in all patients versus 26.8% (95% CI, 16.2 to 37.4) and 8.2% (95% CI, 1.3 to 15.1), respectively, in patients with ESR1 mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Elacestrant, EMERALD: FDA review of the ESR1-mutated subgroup
“The median PFS was 3.8 months (95% CI, 2.2 to 7.3) in the elacestrant arm and 1.9 months (95% CI, 1.9 to 2.1) in the SOC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By contrast, the benefit-risk assessment in patients without ESR1 mutations was not favorable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Elacestrant, EMERALD: duration of prior CDK4/6 inhibitor therapy
Elacestrant, EMERALD: safety
“Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: imlunestrant
Imlunestrant, EMBER-3: FDA approval of monotherapy
Imlunestrant, EMBER-3: primary results
“Overall, 874 patients underwent randomization, with 331 assigned to imlunestrant, 330 to standard therapy, and 213 to imlunestrant–abemaciclib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the overall population, the median progression-free survival was 5.6 months with imlunestrant and 5.5 months with standard therapy (hazard ratio for progression or death, 0.87; 95% CI, 0.72 to 1.04; P = 0.12).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of grade 3 or higher adverse events was 17.1% with imlunestrant, 20.7% with standard therapy, and 48.6% with imlunestrant–abemaciclib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imlunestrant, EMBER-3: updated overall survival
“In patients with ESR1 m, median OS (mOS) was 34.5 months for imlunestrant versus 23.1 months for SOC [hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.43-0.86, P = 0.0043, boundary for significance not reached].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: vepdegestrant
Vepdegestrant, VERITAC-2: FDA approval
Vepdegestrant, VERITAC-2: primary results
“Among all the patients, the median progression-free survival was 3.8 months (95% CI, 3.7 to 5.3) with vepdegestrant and 3.6 months (95% CI, 2.6 to 4.0) with fulvestrant (hazard ratio, 0.83 [95% CI, 0.69 to 1.01]; P = 0.07).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events of grade 3 or higher occurred in 23.4% of the patients in the vepdegestrant group and in 17.6% of the patients in the fulvestrant group. Adverse events led to treatment discontinuation in 2.9% and 0.7% of the patients, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: camizestrant
Camizestrant, SERENA-6: first-line switch at ESR1 mutation detection
Camizestrant, SERENA-4: first-line trial in unselected patients
Giredestrant plus everolimus, evERA: primary results
“Patients were randomized 1:1 to giredestrant plus everolimus (giredestrant-everolimus) or standard endocrine therapy (i.e., exemestane, fulvestrant, or tamoxifen) plus everolimus (standard endocrine therapy-everolimus).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“median progression-free survival was 10.0 months with giredestrant-everolimus and 5.5 months with standard endocrine therapy-everolimus (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.27 to 0.54; P<0.001). In the overall study population, median progression-free survival was 8.8 versus 5.5 months, respectively (HR, 0.56; 95% CI, 0.44 to 0.71; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common adverse events in both groups were stomatitis (47.3% and 48.9%, respectively), diarrhea (26.9% and 22.6%), and anemia (23.6% and 21.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote